EBMT 2024 | Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti
• 15 Apr 2024
Jacopo Mariotti, MD, Humanitas Research Hospital, Milan, Italy, discusses the findings of a single-center retrospective study that compared salvage therapy with checkpoint inhibitors versus brentuximab vedotin in patients receiving allogeneic stem cell transplantation (alloSCT) for relapsed/refractory (R/R) Hodgkin lymphoma (HL). Salvage therapy with checkpoint inhibitors resulted in a lower incidence of relapse, confirming the findings of prior studies in this patient population. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
